# Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

> **NCT03832361** · PHASE2 · RECRUITING · sponsor: **Alessandro Santin** · enrollment: 50 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** IMGN853

## Key facts

- **NCT ID:** NCT03832361
- **Lead sponsor:** Alessandro Santin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-15
- **Primary completion:** 2026-10
- **Final completion:** 2028-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832361, "Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03832361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*